Co-transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in human gastric cancer

Zhang,Ya-Fei; Zhang,Bi-Cheng; Zhang,An-Ran; Wu,Ting-Ting; Liu,Jian; Yu,Li-Fang; Wang,Wei-Xing; Gao,Jian-Fei; Fang,Dian-Chun; Rao,Zhi-Guo

doi:10.3892/or.2013.2663

Co-transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in human gastric cancer

Authors:
- Ya-Fei Zhang
- Bi-Cheng Zhang
- An-Ran Zhang
- Ting-Ting Wu
- Jian Liu
- Li-Fang Yu
- Wei-Xing Wang
- Jian-Fei Gao
- Dian-Chun Fang
- Zhi-Guo Rao
View Affiliations

Affiliations: Department of Oncology, Wuhan General Hospital of Guangzhou Command, People's Liberation Army, Wuhan, Hubei 430070, P.R. China, Department of Gastroenterology, Southwest Hospital, Third Military Medical University, Chongqing 400038, P.R. China
Published online on: August 7, 2013 https://doi.org/10.3892/or.2013.2663
Pages: 1989-1995

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Induction of murine double minute 2 (MDM2) expression is thought to be a determinant of resistance to p53 gene therapy for cancer. Previous studies have revealed that ribosomal protein L23 (RPL23) inhibits MDM2-mediated p53 degradation through direct binding to MDM2. In addition, ectopically expressed RPL23 was reported to interact with MDM2 in both the nucleus and cytoplasm, by which RPL23 indirectly inhibited MDM2-p53 binding. Based on the known molecular properties of the RPL23 protein, it was speculated that co-transduction of RPL23 may protect wild‑type p53 protein from MDM2-mediated inactivation and, thus, improve the effect of delivering therapeutic exogenous p53. To test this hypothesis, we constructed a bicistronic adenoviral vector expressing both the RPL23 and p53 genes (Ad-RPL23/p53) and compared its tumor-suppressor activity in human gastric cancer with that of a single gene vector for p53 (Ad-p53). In the in vivo and in vitro experiments, we observed that treatment with Ad-RPL23/p53 resulted in a stronger antitumor response compared to that obtained using Ad-p53. Moreover, the antitumor response of the bicistronic adenovirus was obtained not only in MGC803 cells (endogenous mutant p53) but also in MKN45 cells (endogenous wild‑type p53) which were initially resistant to p53 gene transfer, indicating that co-transduction of RPL23 also expanded the utility of p53 gene therapy. Furthermore, in an orthotopic nude mouse model of human gastric cancer, we found that the survival benefit was greater after Ad-RPL23/p53 treatment than after Ad-p53. Taken together, the data presented here demonstrate that co-transduction of RPL23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in models of human gastric cancer and support the use of this strategy for cancer treatment.

View Figures

View References

1	Cheok CF, Verma CS, Baselga J and Lane DP: Translating p53 into the clinic. Nat Rev Clin Oncol. 8:25–37. 2011. View Article : Google Scholar
2	Brown CJ, Lain S, Verma CS, Fersht AR and Lane DP: Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 9:862–873. 2009. View Article : Google Scholar : PubMed/NCBI
3	Lane DP and Lain S: Therapeutic exploitation of the p53 pathway. Trends Mol Med. 8(Suppl 4): S38–S42. 2002. View Article : Google Scholar : PubMed/NCBI
4	Lane DP, Cheok CF and Lain S: p53-based cancer therapy. Cold Spring Harb Perspect Biol. 2:a0012222010.PubMed/NCBI
5	Momand J, Zambetti GP, Olson DC, George D and Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1237–1245. 1992. View Article : Google Scholar : PubMed/NCBI
6	Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature. 387:296–299. 1997. View Article : Google Scholar : PubMed/NCBI
7	Kubbutat MH, Jones SN and Vousden KH: Regulation of p53 stability by Mdm2. Nature. 387:299–303. 1997. View Article : Google Scholar : PubMed/NCBI
8	Marine JC and Lozano G: Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ. 17:93–102. 2010. View Article : Google Scholar : PubMed/NCBI
9	Moll UM and Petrenko O: The MDM2-p53 interaction. Mol Cancer Res. 1:1001–1008. 2003.PubMed/NCBI
10	Shangary S and Wang S: Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res. 14:5318–5324. 2008. View Article : Google Scholar : PubMed/NCBI
11	Wiman KG: Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ. 13:921–926. 2006. View Article : Google Scholar : PubMed/NCBI
12	van Beusechem VW, van den Doel PB and Gerritsen WR: Conditionally replicative adenovirus expressing degradation-resistant p53 for enhanced oncolysis of human cancer cells overexpressing murine double minute 2. Mol Cancer Ther. 4:1013–1018. 2005.
13	Nishizaki M, Sasaki J, Fang B, Atkinson EN, Minna JD, Roth JA and Ji L: Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res. 64:5745–5752. 2004. View Article : Google Scholar : PubMed/NCBI
14	Dai MS, Zeng SX, Jin Y, Sun XX, David L and Lu H: Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol. 24:7654–7668. 2004. View Article : Google Scholar : PubMed/NCBI
15	Jin A, Itahana K, O’Keefe K and Zhang Y: Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol. 24:7669–7680. 2004. View Article : Google Scholar : PubMed/NCBI
16	Zhang Y, Shi Y, Li X, et al: Inhibition of the p53-MDM2 interaction by adenovirus delivery of ribosomal protein L23 stabilizes p53 and induces cell cycle arrest and apoptosis in gastric cancer. J Gene Med. 12:147–156. 2010.PubMed/NCBI
17	Ohashi M, Kanai F, Ueno H, et al: Adenovirus mediated p53 tumour suppressor gene therapy for human gastric cancer cells in vitro and in vivo. Gut. 44:366–371. 1999. View Article : Google Scholar : PubMed/NCBI
18	Jiang XH, Wong BC, Lin MC, et al: Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-κB activation in gastric cancer cells. Oncogene. 20:8009–8018. 2001.PubMed/NCBI
19	Sun S, Li XM, Li XD and Yang WS: Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines. Cancer Biother Radiopharm. 20:173–180. 2005. View Article : Google Scholar : PubMed/NCBI
20	Kim HJ, Cho HI, Han YH, et al: Efficient transduction with recombinant adenovirus in EBV-transformed B lymphoblastoid cell lines. J Biochem Mol Biol. 37:376–382. 2004. View Article : Google Scholar : PubMed/NCBI
21	Yang HY, Zhang WG, Ma LP, Wang SW and Zhang ZY: An approach to enhancing the phototoxicity of a novel hypocrellin congener to MGC803 cells. Dyes Pigments. 51:103–110. 2001. View Article : Google Scholar
22	Furukawa T, Kubota T, Watanabe M, Kitajima M and Hoffman RM: Orthotopic transplantation of histologically intact clinical specimens of stomach cancer to nude mice: correlation of metastatic sites in mouse and individual patient donors. Int J Cancer. 53:608–612. 1993. View Article : Google Scholar
23	Shi J, Wei PK, Zhang S, et al: OB glue paste technique for establishing nude mouse human gastric cancer orthotopic transplantation models. World J Gastroenterol. 14:4800–4804. 2008. View Article : Google Scholar : PubMed/NCBI
24	Ozaki T and Nakagawara A: p53: the attractive tumor suppressor in the cancer research field. J Biomed Biotechnol. 2011:6039252011. View Article : Google Scholar : PubMed/NCBI
25	Amaral JD, Xavier JM, Steer CJ and Rodrigues CM: Targeting the p53 pathway of apoptosis. Curr Pharm Des. 16:2493–2503. 2010. View Article : Google Scholar : PubMed/NCBI
26	Levine AJ: p53, the cellular gatekeeper for growth and division. Cell. 88:323–331. 1997. View Article : Google Scholar : PubMed/NCBI
27	Tisato V, Norcio A, Voltan R, Celeghini C, Zella D and Secchiero P: MDM2 non-genotoxic inhibitors as innovative therapeutic approaches for the treatment of pediatric malignancies. Curr Med Chem. 20:2226–2236. 2013. View Article : Google Scholar : PubMed/NCBI
28	Graat HC, Carette JE, Schagen FH, et al: Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53. Mol Cancer Ther. 6:1552–1561. 2007. View Article : Google Scholar : PubMed/NCBI
29	Tango Y, Fujiwara T, Itoshima T, et al: Adenovirus-mediated p14^ARF gene transfer cooperates with Ad5CMV-p53 to induce apoptosis in human cancer cells. Hum Gene Ther. 13:1373–1382. 2002.PubMed/NCBI
30	Huang Y, Tyler T, Saadatmandi N, Borgstrom P and Gjerset RA: Enhanced tumor suppression by a p14ARF/p53 bicistronic adenovirus through increased p53 protein translation and stability. Cancer Res. 63:3646–3653. 2003.PubMed/NCBI